30. September 2024We’re thrilled to announce that we have secured new funding to advance our innovative therapy for hair loss! In September,…- 9. September 2024We’re excited to announce that Prof. Dr. Alexander Steinkasserer, our Managing Partner and Co-founder, will present new data on behalf…
19. July 2024Our co-founder Prof. Dr. Alexander Steinkasserer talked to Laborjournal about the serendipitous discovery of sCD83’s ability to stimulate hair growth.…
28. June 2024We are excited that Dr. Manfred Gröppel will present Mallia’s approach to combating hair loss during the Start-up Pitches. BayOConnect…
4. June 2024Dr. Manfred Gröppel convinced a jury of technology transfer professionals with a pitch presentation of our approach to combatting hairloss…- 4. June 2024We presented a pitch on our founding story and our development of sCD83 as a new therapy for the topical…
- 28. May 2024Prof. Dr. Alexander Steinkasserer und Dr. Manfred Gröppel are excited to be there and to discuss our novel approach to…
4. December 2023We are proud to be among the innovative startups driving change in the pharmaceutical landscape, and we look forward to…
11. July 2023Erlangen, Germany, July 11, 2023 / Mallia Therapeutics GmbH, a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of…- 16. June 2023Differential Modulation of Dendritic Cell Biology by Endogenous and Exogenous Aryl Hydrocarbon Receptor Ligands. Sadeghi Shermeh A, Royzman D, Kuhnt…
